Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

108.97 -2.51 (-2.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
64 65 Next >
96 Biggest Movers From Yesterday
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex... 
Via Benzinga
Hopes For A Peace Accord
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
Via Talk Markets
Vaccine Stocks Pfizer, Moderna Pop As 'Deltacron' Emerges, China Locks Down
Pfizer CEO Albert Bourla says a fourth booster shot is needed "right now." 
Via Investor's Business Daily
Why Is Novavax (NVAX) Stock in the Spotlight Today?
Novavax is once again in the spotlight as China reports near-record numbers of Covid cases. What's going on with NVAX stock? 
Via InvestorPlace
Here's Why BioNTech Shares Are Rising On Monday
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 14.8% at $155.65. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment. 
Via Benzinga
Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher
U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session. The Dow... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 48.0% to $20.95 during Monday's regular session. The company's market cap stands at $1.0 billion.... 
Via Benzinga
GeoVax Labs Retains CATO SMS To Manage Its Mid-Stage COVID-19 Vaccine Trials
GeoVax Labs Inc (NASDAQ: GOVX) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the... 
Via Benzinga
Pfizer-BioNTech's COVID-19 Shot Moderately Effective Against Omicron In Kids Aged 5 to 15, CDC Study Shows
The Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15.... 
Via Benzinga
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care
The IBD/TIPP Poll shows Covid has fallen among Americans' priorities. 
Via Investor's Business Daily
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116... 
Via Benzinga
50 Stocks Moving In Monday's Mid-Day Session
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share. AgriFORCE Growing Systems,... 
Via Benzinga
Benzinga Bulls And Bears Of The Past Week: Shopify, Palantir, Apple, Meta, Twitter, Johnson & Johnson, American Express And More
Benzinga has examined the prospects for many investor favorite stocks over the... 
Via Benzinga
Johnson & Johnson's COVID-19 Vaccine Less Effective Against Hospitalization, French Study Shows
According to a large French study, the risk of hospitalization after vaccination with Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine was about five times... 
Via Benzinga
Markets Fall As Russia-Ukraine Tensions Escalate; American Express, Boeing See Sharp Drops
U.S. indices finished lower as the Russian invasion of Ukraine continues to escalate. The conflict has weighed on stocks and economic sentiment whi... 
Via Benzinga
Pfizer/BioNTech's COVID-19 Vaccine Mere 12% Effective In Kids 5-11 Years, New York Study Shows
According to a published study, Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) two-dose COVID-19 vaccine provided very little protection for... 
Via Benzinga
DarioHealth Enters Into Strategic Agreement With Sanofi U.S.
Novel Strategic Agreement focuses on commercial growth for Dario and the development of Digital Health Solutions on Dario’s platform. 
Via Talk Markets
Maravai LifeSciences Rejects Sartorius' $11B Takeover Bid: Reuters
Germany-based laboratory equipment supplier Sartorius AG has approached Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) with an $11 billion acquisition offer... 
Via Benzinga
Moderna’s Covid Shot Alone Isn’t Enough to Revitalize a Sagging Stock
Moderna has to focus on the rest of its pipeline to keep MRNA stock relevant and profitable as Covid vaccine revenues taper off by 2023. 
Via InvestorPlace
Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests
The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc's (NYSE: PFE) / BioNTech SE... 
Via Benzinga
Where BioNTech Stands With Analysts
BioNTech (NASDAQ:BNTX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0... 
Via Benzinga
Blood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study Shows
A large study into rare blood clots linked with AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine found between one and three cases per million, and only after... 
Via Benzinga
BioNTech, Medigene Ink Immunotherapy Pact Against Cancer
BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer... 
Via Benzinga
Why Novavax Has Limited Downside from Here
As countries potentially adopt a once yearly vaccination booster schedule for Covid-19, you can expect steady earnings for NVAX stock. 
Via InvestorPlace
Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline
Moderna Inc (NASDAQ: MRNA) said it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection... 
Via Benzinga
Pfizer/BioNTech's Omicron-Targeted COVID-19 To Miss March Timeline: Reuters
Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart
Macy's Inc (NYSE:M) retail stores have something for everyo... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
US Senate Narrowly Votes In Favor Of Biden's Nominee Robert Califf To Lead FDA For Second Time
By a narrow vote of 50-46, the Senate has confirmed Robert Califf to run the FDA. Califf, who previously served as the FDA commissioner from February 2016 to January... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
64 65 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.